Azithromycin SR
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Upper Respiratory Tract Infection
Conditions
Upper Respiratory Tract Infection
Trial Timeline
Nov 1, 2006 → May 1, 2007
NCT ID
NCT00393835About Azithromycin SR
Azithromycin SR is a phase 3 stage product being developed by Pfizer for Upper Respiratory Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00393835. Target conditions include Upper Respiratory Tract Infection.
What happened to similar drugs?
6 of 14 similar drugs in Upper Respiratory Tract Infection were approved
Approved (6) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00998309 | Pre-clinical | Completed |
| NCT00393835 | Phase 3 | Completed |
| NCT00360464 | Phase 3 | Completed |
| NCT00360295 | Phase 3 | Completed |
Competing Products
20 competing products in Upper Respiratory Tract Infection